Clinical trials: Immune System Disorder (Healthy Volunteer)
Asthma, Healthy
Factors Involved in Asthma and Airway Inflammation
Asthma is the third leading cause of preventable admissions to the hospital in the United States. Deaths and diseases associated with asthma increase every year. Asthma is a disorder of airway inflammation.
- Trial name
- NCT00001887
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Autoimmune Diseases
Safety and Tolerability of GX-P1 in Healthy Male Volunteers
This study is a single-center, double-blind, placebo-controlled, phase I study with healthy male volunteers receiving ascending single dose of GX-P1
- Trial name
- NCT04298749
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
HIV Infections
TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
The purpose of this study is to investigate the effect of steady-state concentrations of raltegravir (administered as 400 mg, twice daily) on the steady-state pharmacokinetics of TMC278 (25 mg, once daily), and vice versa.
- Trial name
- NCT01288755
- Testing
- TMC278, Raltegravir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
This study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants…
- Trial name
- NCT07751315
- Testing
- Ia:QLS2404 very low dose, Ia:QLS2404 low dose, Ia:QLS2404 middle dose
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
HIV Infections
A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
This is an open-label, single-dose, four-period, four sequential, and crossover study conducted to assess the relative bioavailability of GSK3640254 mesylate tablets and GSK3640254 mesylate capsules (in the presence of a moderate…
- Trial name
- NCT04128293
- Testing
- GSK3640254 Tablet, GSK3640254 Capsule
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy, Systemic Lupus Erythematosus
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
The purpose of this study is to investigate the safety and tolerability of LY4298445 in healthy participants and in participants with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA).
- Conditions
- Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- NCT07276958
- Testing
- LY4298445
- Where
- 10 sites in Australia, China and 1 more
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind, placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male and female patients with atopic dermatitis.
- Trial name
- NCT04271514
- Testing
- RPT193
- Where
- 14 sites in United States, Netherlands
- Volunteers
- 103 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Autoimmune Diseases
Phase 1 Study Accessing the Safety and Tolerability of CBP-307
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CBP-307 following oral single and multiple escalating dose administration in healthy subjects.
- Trial name
- NCT02280434
- Testing
- CBP-307
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Connect Biopharm LLC
Asthma, Copd
A Study to Obtain Normal Values of Inflammatory Variables From Healthy Subjects
Smoking induces an inflammatory reaction in the airways which can ultimately result in persistent damage and the development of a Chronic Obstructive Pulmonary Disease (COPD). However, not all subjects who smoke end up with COPD.
- Trial name
- NORM (NCT00848406)
- Where
- Netherlands
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
HIV Infections
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations.
- Trial name
- NCT00189904
- Testing
- IMVAMUNE (MVA-BN)
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- Bavarian Nordic
Healthy Volunteers, Multiple Sclerosis
Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
In this first in human study the aim is to assess the safety, pharmacokinetics and pharmacodynamics of 2B3-201 in a randomized, first in human, double-blind, placebo- and active comparator- controlled 3-way crossover study in 18…
- Trial name
- NCT02048358
- Testing
- 2B3-201, Methylprednisolone hemisuccinate
- Where
- 2 sites in Netherlands
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BBB-Therapeutics B.V.
Asthma
A Comparison of VR647 and Conventionally Nebulized Budesonide in Healthy Volunteers and Adult Asthma Subjects
This is a three part, randomized, open-label, crossover, Phase 1 trial in adults. Parts 1 and 2 will enroll healthy male and female subjects. Part 3 will enroll subjects with mild asthma.
- Trial name
- NCT04032834
- Testing
- VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with mouthpiece, VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System (AKITA JET) with facemask, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer (PARI VIOS) with mouthpiece
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Vectura Limited
Bioequivalence, Asthma
Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
- Trial name
- NCT05085587
- Testing
- Test, Reference
- Where
- Greece
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Respirent Pharmaceuticals Co Ltd.
Healthy Volunteers, Idiopathic Environmental Intolerance
Study of Cognitive and Behavioural Biases in People With Idiopathic Environmental Intolerance (IEI) Versus Healthy Controls
Symptoms that patients attribute to the environment when no environmental cause can be identified are known as "idiopathic environmental intolerance" (IEI).
- Trial name
- BELIEFS VS (NCT06800976)
- Where
- France
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Asthma
A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists
This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled…
- Trial name
- NCT05110976
- Testing
- AZD8630
- Where
- 29 sites in United States, Germany and 1 more
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
C3 Glomerulopathy, IgA Nephropathy
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G]…
- Trial name
- NCT05083364
- Testing
- ARO-C3
- Where
- 16 sites in Australia, Georgia and 5 more
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
HIV, AIDS
Bioequivalence Study of Pediatric Formulations to Treat HIV Infection
The purpose of the study is to determine the bioavailability/bioequivalence of two pediatric formulations (tablet and reconstitutable suspension) of lamivudine/zidovudine/ nevirapine in comparison to an innovator product.
- Trial name
- NCT01469520
- Testing
- Epivir®, Retrovir® and Viramune®, Lamivudine, Zidovudine and nevirapine, Lamivudine, zidovudine, nevirapine
- Where
- Nigeria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Elim Pediatric Pharmaceuticals Inc.
Healthy Participants, Atopic Dermatitis
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT06564389
- Testing
- PF-07832837
- Where
- 5 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Pfizer
Rheumatoid Arthritis (RA)
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single-dose subcutaneous injection of SHR-3045 in healthy subjects.
- Trial name
- NCT07200596
- Testing
- SHR-3045 Injection
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Immune System Disorder (Healthy Volunteer)
A Study to Determine the Effect of Multiple Oral Doses and Regimens of KD025 in Healthy Male and Post-menopausal Female Subjects
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple oral doses and regimens of KD025 in healthy male and post-menopausal female participants.
- Trial name
- NCT05918588
- Testing
- Belumosudil mesylate
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.